2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea

• Published in: Diabetes & metabolism journal Vol. 43; no. 4; pp. 398 - 406
• Main Authors: Kim, Mee Kyoung, Ko, Seung-Hyun, Kim, Bo-Yeon, Kang, Eun Seok, Noh, Junghyun, Kim, Soo-Kyung, Park, Seok-O, Hur, Kyu Yeon, Chon, Suk, Moon, Min Kyong, Kim, Nan-Hee, Kim, Sang Yong, Rhee, Sang Youl, Lee, Kang-Woo, Kim, Jae Hyeon, Rhee, Eun-Jung, Chun, SungWan, Yu, Sung Hoon, Kim, Dae Jung, Kwon, Hyuk-Sang, Park, Kyong Soo
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Diabetes Association / Daehan Dangnyobyeong Hakoe 01.08.2019; Korean Diabetes Association; 대한당뇨병학회
• Subjects: Adult; Antihypertensive Agents - therapeutic use; Asian people; Blood pressure; Body mass index; Cardiovascular disease; Clinical medicine; Clinical practice guidelines; Clinical trials; Diabetes; diabetes mellitus, type 2; Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - epidemiology; Diabetic Nephropathies - drug therapy; diagnosis; Glucagon-Like Peptide-1 Receptor - agonists; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Hypertension; Hypoglycemia; Hypoglycemic Agents - therapeutic use; Obesity; Obesity - drug therapy; Plasma; practice guideline; Prevalence; Republic of Korea - epidemiology; Review; Risk factors; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Statins; Stroke; therapeutics; Weight control; Weight Loss; 내과학; Republic of Korea; Practice guideline; Diagnosis; Diabetes mellitus, type 2; Therapeutics
• ISSN: 2233-6079; 2233-6087
• DOI: 10.4093/dmj.2019.0137

The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the 6th Clinical Practice Guidelines in 2019. Targets of glycemic, blood pressure, and lipid control in type 2 diabetes mellitus (T2DM) were updated. The obese and overweight population is increasing steadily in Korea, and half of the Koreans with diabetes are obese. Evidence-based recommendations for weight-loss therapy for obesity management as treatment for hyperglycemia in T2DM were provided. In addition, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations.